Amidephrine Mesylate

Amidephrine Mesylate

SCHEMBL122479

CNCC(O)c1cccc(NS(C)(=O)=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 7/20 0.58
ADRB2 P07550 5/20 0.58
ADRB1 P08588 4/20 0.58
ADRA1A P35348 4/20 0.58
HIF1A Q16665 3/20 0.58
SLC6A3 Q01959 3/20 0.58
ADRA2A P08913 2/20 0.58
TSHR P16473 2/20 0.58
ADRA2B P18089 2/20 0.58
ADRA2C P18825 2/20 0.58
DRD1 P21728 2/20 0.58
ADRA1B P35368 2/20 0.58
DRD3 P35462 2/20 0.58
HTR1A P08908 1/20 0.58
NFKB1 P19838 1/20 0.58
HTR7 P34969 1/20 0.58
RAB9A P51151 1/20 0.58
KDM4E B2RXH2 4/20 0.56
LMNA P02545 3/20 0.56
BLM P54132 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amidephrine Mesylate SCHEMBL122478 0.98 ADRB3 (0.56) ADRB3ADRB2ADRB1ADRA1AHIF1A
Methane SCHEMBL10481131 0.88 HIF1A (0.55) ADRB3ADRB2ADRB1ADRA1AHIF1A
SCHEMBL13139256 0.84 ALDH1A1 (0.51) ADRB3ADRB2ADRB1ADRA1AADRA2C
SCHEMBL7108854 0.84 ALDH1A1 (0.51) ADRB3ADRB2ADRB1ADRA1AADRA2B
SCHEMBL11420225 0.83 ADRB3 (0.61) ADRB3ADRB2ADRB1ADRA1AADRA2C
SCHEMBL9688351 0.83 ADRB2 (0.72) ADRB3ADRB2ADRB1ADRA1AHIF1A
Hydrochloric Acid SCHEMBL9216885 0.82 ADRB3 (0.59) ADRB3ADRB2ADRB1ADRA1AADRA2C
Hydrochloric Acid SCHEMBL9216889 0.82 ADRB3 (0.59) ADRB3ADRB2ADRB1ADRA1AADRA2C
SCHEMBL245468 0.79 MEN1 (0.60) ADRB3ADRB2ADRB1KDM4ELMNA
SCHEMBL6317925 0.79 SLC6A3 (0.60) ADRB3ADRB2ADRB1ADRA1AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233997-A Tetrahedral antibodies 生物分子控股有限责任公司 2024-12-31 CN claimed
EP-4463485-A2 TETRAHEDRAL ANTIBODIES Biomolecular Holdings LLC (US) 2024-11-20 EP claimed
CN-118384290-A Hybrid immunoglobulins containing non-peptide linkages 生物分子控股有限责任公司 2024-07-26 CN claimed
US-20240225978-A1 METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS Bokman, Christine Lynn (US) 2024-07-11 US claimed
US-20230310420-A1 METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION UNIV MIDWESTERN (US) 2023-10-05 US claimed
WO-2023137373-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 WO claimed
WO-2023137387-A2 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 WO claimed
US-20230220116-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-13 US claimed
US-20230220115-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-13 US claimed
EP-4178615-A1 TETRAHEDRAL ANTIBODIES Biomolecular Holdings LLC (US) 2023-05-17 EP claimed
US-20050031676-A1 Method and device for enhancing transdermal agent flux ALZA CORPORATION 2005-02-10 US claimed
US-20050025778-A1 Microprojection array immunization patch and method ALZA CORPORATION 2005-02-03 US claimed
WO-2005002453-A1 MICROPROJECTION ARRAY IMMUNIZATION PATCH AND METHOD ALZA CORPORATION (US) 2005-01-13 WO claimed
US-20040115167-A1 Drug delivery device and method having coated microprojections incorporating vasoconstrictors ALZA CORPORATION 2004-06-17 US claimed
WO-2004030743-A2 DRUG DELIVERY DEVICE HAVING COATED MICROPROJECTIONS INCORPORATING VASOCONSTRICTORS ALZA CORPORATION (US) 2004-04-15 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5684018-A Acyloxyisopropyl carbamates as prodrugs for amine drugs MERCK & CO., INC. (US) 1997-11-04 US claimed
WO-1996018605-A1 ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS MERCK & CO., INC. (US) 1996-06-20 WO claimed
EP-0170193-B1 FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 1991-12-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310420-A1 METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION ADRA2A, ADRA2C, ADRB2 ADRB3 6/4885ADRB2 3/4885ADRB1 8/4885
US-20230220115-A1 TETRAHEDRAL ANTIBODIES FCGR3B, FCGR2A, FCGR1A ADRB3 4587/4885ADRB2 4833/4885ADRB1 4801/4885
US-20230220116-A1 TETRAHEDRAL ANTIBODIES FCGR3B, FCGR2A, FCGR1A ADRB3 4587/4885ADRB2 4833/4885ADRB1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.